Breast cancer drug tamoxifen tested as new hope for cystic fibrosis
NCT ID NCT07289035
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether tamoxifen citrate, a drug commonly used for breast cancer, is safe and tolerable for adults with cystic fibrosis who cannot take current CFTR modulator drugs. Thirty-five participants will take one tablet daily for six months and visit the clinic every 28 days. The main goal is to track side effects and see if the drug can help manage the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tamoxifen citrate (a drug usually used for breast cancer, repurposed here)
What this could lead to
If it works, this could point toward a new treatment option for cystic fibrosis patients who cannot use current CFTR modulator drugs.
What could go wrong
This is an early phase 2 trial with only 35 participants, so results may not apply to everyone. Tamoxifen also carries risks like blood clots and liver issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS - COMPLETE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UOC Fibrosi Cistica - AOUI Verona
Verona, Veneto, 37126, Italy